Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ZG006 |
| Synonyms | |
| Therapy Description |
ZG006 is a trispecific T-cell engager targeting two epitopes of DLL3 and CD3, which potentially induces cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing DLL3 (Ann Oncol (2024) 35 (Suppl_2): S532-S533, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZG006 | ZG-006|ZG 006 | CD3 Antibody 119 DLL3 Antibody 10 | ZG006 is a trispecific T-cell engager targeting two epitopes of DLL3 and CD3, which potentially induces cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing DLL3 (Ann Oncol (2024) 35 (Suppl_2): S532-S533, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06592638 | Phase I | ZG006 | A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | Recruiting | USA | 0 |